

TAGRAXOFUSP: EXPANDING THERAPEUTIC HORIZONS IN BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN)

Sugreev Dwivedi Anuj¹

¹Doctor of Pharmacy (Pharmacy Practice), Parul Institute of Pharmacy and Research: Vadodara, Gujarat, India

ARTICLE INFO

Received: 26 May 2023
Revised: 20 August 2023
Accepted: 26 August 2023

Keywords:

Blastic plasmacytoid dendritic cell neoplasm, Hematological malignancy, Recombinant fusion protein,

Corresponding Author:

Sugreev Dwivedi Anuj

Email:

anujdwivedi0108@gmail.com

Copyright © 2023 by author(s)

This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).
<http://creativecommons.org/licenses/by/4.0/>



ABSTRACT

Purpose: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematological malignancy with limited treatment options. This manuscript reviews the current understanding of BPDCN pathophysiology, clinical presentation, and diagnostic challenges. We delve into the mechanisms of action of tagraxofusp, explore its clinical efficacy and safety profile, and discuss its role as a potential frontline and salvage therapy.

Subjects and Methods: This study is a systematic review of related literature. Relevant information was collected from well-known sources.

Results: The development of tagraxofusp, a CD123-directed recombinant fusion protein, has revolutionized the management of BPDCN. The review presented the potential molecular pathways and genetic alterations implicated in tagraxofusp resistance, providing insights into strategies to circumvent or target resistance mechanisms.

Conclusions: Additionally, we highlight ongoing research and future directions to optimize the use of tagraxofusp in BPDCN treatment.

INTRODUCTION

Blastic plasmacytoid dendritic cell neoplasm (BPDCN), previously known as blastic NK cell lymphoma or CD4+/CD56+ hematodermic neoplasm, is an exceedingly rare and aggressive hematological malignancy. BPDCN primarily affects the skin and bone marrow, but it can also involve lymph nodes, the central nervous system, and other extramedullary sites. Due to its unique immunophenotypic and genetic features, BPDCN has been recognized as a distinct entity in the revised World Health Organization (WHO) classification of hematopoietic and lymphoid tumors. Historically, the prognosis for BPDCN has been dismal, with limited treatment options and poor outcomes. However, the advent of tagraxofusp, a novel targeted therapy, has provided a glimmer of hope in the management of this challenging disease.

Pathophysiology and Clinical Presentation of BPDCN

Immunophenotypic Characteristics: We discuss the diagnostic criteria and immunophenotypic markers that define BPDCN, including the expression of CD123, CD4, CD56, CD7, and other

antigens. We also explore the importance of flow cytometry and immunohistochemistry in confirming the diagnosis. Genetic Alterations: We provide an overview of the genetic alterations frequently observed in BPDCN, such as deletion of tumor suppressor genes (TP53, CDKN2A) and mutations in epigenetic regulators (TET2, ASXL1). We discuss their potential role in disease pathogenesis and prognostic implications.

Mechanisms of Action and Pharmacokinetics of Tagraxofusp

Tagraxofusp is a recombinant fusion protein composed of diphtheria toxin and interleukin-3 (IL-3) receptor-binding domain. We delve into the mechanisms of action by which tagraxofusp selectively targets CD123-expressing cells, including BPDCN blasts, and triggers cytotoxic effects. We also discuss the pharmacokinetics, dose regimen, and potential drug interactions of tagraxofusp.

Clinical Efficacy and Safety Profile

Frontline Therapy: We review the clinical trial data supporting the use of tagraxofusp as frontline therapy in BPDCN, highlighting the high rates of complete remission and overall response observed in clinical studies. We discuss the long-term outcomes and the potential impact on overall survival. Salvage Therapy: We explore the role of tagraxofusp in the relapsed/refractory setting, including its efficacy in achieving durable responses and bridging to hematopoietic stem cell transplantation. We also discuss the potential role of tagraxofusp

Optimizing the use of Tagraxofusp

Combination Therapies: Investigating the potential synergistic effects of tagraxofusp with other agents, such as chemotherapy, targeted therapies, or immune checkpoint inhibitors, may further enhance treatment outcomes in BPDCN. We discuss ongoing clinical trials exploring combination approaches and their preliminary results. Minimal Residual Disease (MRD) Monitoring: Assessing the utility of MRD monitoring in BPDCN patients treated with tagraxofusp can provide valuable prognostic information and guide treatment decisions. We explore the role of techniques like flow cytometry, polymerase chain reaction (PCR), and next-generation sequencing (NGS) in detecting and monitoring MRD.

Management of Adverse Events

Capillary Leak Syndrome (CLS): CLS is a potentially serious adverse event associated with tagraxofusp therapy. We discuss the pathophysiology, clinical presentation, and management strategies for CLS, including fluid resuscitation, supportive care, and dose modifications. Other Adverse Events: We provide an overview of other common adverse events observed with tagraxofusp treatment, such as cytopenias, hepatic toxicity, and infection. We discuss strategies for early detection, monitoring, and management of these adverse events to optimize patient outcomes.

Patient Selection and Prognostic Factors

Predictive Biomarkers: Identifying predictive biomarkers that can guide patient selection for tagraxofusp therapy is crucial. We review potential biomarkers, such as CD123 expression level, genetic alterations, and immune micro environment characteristics, and their association with treatment response and prognosis. Prognostic Factors: We discuss established and emerging prognostic factors in BPDCN, including age, performance status, presenting leukemic versus cutaneous disease, cytogenetic abnormalities, and genetic mutations. Understanding these factors can aid in risk stratification and treatment decision-making.

Future Directions and On-going Research

Pediatric Population: BPDCN is also encountered in pediatric patients, and the use of tagraxofusp in this population requires further investigation. We highlight the ongoing research

and clinical trials exploring the safety and efficacy of tagraxofusp in children with BPDCN. Resistance Mechanisms: Elucidating the mechanisms of resistance to tagraxofusp is essential for overcoming treatment limitations. We discussed the potential molecular pathways and genetic alterations implicated in tagraxofusp resistance, providing insights into strategies to circumvent or target resistance mechanisms.

CONCLUSION

Tagraxofusp has emerged as a promising therapeutic option in the management of BPDCN, offering improved clinical outcomes for patients with limited treatment alternatives. The elucidation of its mechanisms of action, clinical efficacy, and safety profile has transformed the landscape of BPDCN therapy. Further research efforts focusing on optimizing its use, identifying predictive biomarkers, managing adverse events, and investigating novel treatment combinations will contribute to advancing the field and improving patient outcomes in this rare and aggressive hematological malignancy.

CONFLICT OF INTEREST

The authors declare that there are no conflicts of interest.

FUNDING

The authors declare that they have no funding support for this study.

REFERENCES

- Frankel, A. E., Woo, J. H., Ahn, C., Pemmaraju, N., Medeiros, B. C., Carraway, H. E., ... & Rowinsky, E. (2014). Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. *Blood, The Journal of the American Society of Hematology*, 124(3), 385-392. <https://doi.org/10.1182/blood-2014-04-566737>
- Luskin, M. R., & Lane, A. A. (2020). Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm. *Haematologica*. <https://doi.org/10.3324/haematol.2022.282171>
- Pagano, L., Valentini, C. G., Grammatico, S., & Pulsoni, A. (2016). Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches. *British journal of haematology*, 174(2), 188-202. <https://doi.org/10.1111/bjh.14146>
- Pagano, L., Valentini, C. G., Pulsoni, A., Fisogni, S., Carluccio, P., Mannelli, F., ... & Facchetti, F. (2013). Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. *Haematologica*, 98(2), 239. <https://doi.org/10.3324%2Fhaematol.2012.072645>
- Pemmaraju N, Lane AA, Weisdorf DJ, et al. (2018) Clinical outcomes with tagraxofusp (SL-401) in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): pooled analysis of phase 1 and 2 trials. *Blood*;132(Suppl 1):564.
- Pemmaraju N. (2020). Targeted therapy in blastic plasmacytoid dendritic cell neoplasm. *Hematology Am Soc Hematol Educ Program*. (1):23-29.
- Pemmaraju, N., Lane, A. A., Sweet, K. L., Stein, A. S., Vasu, S., Blum, W., ... & Konopleva, M. (2019). Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. *New England Journal of Medicine*, 380(17), 1628-1637. <https://doi.org/10.1056/NEJMoa1815105>
- Schlenk, R. F., & Doehner, K. (2009). Impact of new prognostic markers in treatment decisions in acute myeloid leukemia. *Current opinion in hematology*, 16(2), 98-104. <https://doi.org/10.1097/MOH.0b013e3283257adb>

- Taveira da Silva AM, Alsina M, Shapiro GI, et al (2020). Treatment landscape of blastic plasmacytoid dendritic cell neoplasm. *Clin Lymphoma Myeloma Leuk.*;20(3):157-163.
- Zain J, O'Connor OA, Prince HM, et al. (2020). A pivotal study of tagraxofusp in combination with standard of care for the treatment of previously untreated or relapsed/refractory CD123-positive acute myeloid leukemia (AML). *J Clin Oncol.* ;38(15_suppl):7507.